Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Pipetting in lab

Through the collaboration, Oxford academics, including Kennedy Investigators Profs. Fiona Powrie and Christopher Buckley, and Dr Brian Marsden, will work with Janssen scientists to develop a cellular map of genes and proteins implicated across a range of immune-mediated inflammatory disorders and characterise pharmacologically relevant therapeutic targets. The agreement was facilitated by Johnson & Johnson Innovation.

Lead Oxford investigator for the project, Professor Holm Uhlig (Nuffield Department of Medicine) said, “This exciting endeavour brings together a world leading group of Janssen and Oxford scientists to form the Cartography collaboration. This project aims to create a detailed cellular map across multiple immune disorders which has the potential to advance the understanding of disease mechanisms, how to treat the right patients with the right medications, and the development of new therapies.”

Speaking of the partnership, Professor Fiona Powrie said, “The Oxford/Janssen collaboration is an extremely exciting initiative. It offers a unique opportunity to define the cellular basis of disease, to identify shared and unique processes across different inflammatory diseases informing the development of personalised medicine approaches.”

Immune mediated inflammatory disorders affect a large proportion of the population. Genetic association studies, functional studies, and clinical observations suggest that there is substantial overlap between immune mediated inflammatory disorders affecting different organ systems, but the cellular mechanisms are largely unknown.

This 3-year data-driven study, will apply the latest molecular and cellular multiomics analysis platforms, and computational methods to deliver insights for target selection and precision medicine for inflammatory disease indications of the intestine, the joint and the skin where existing options for therapeutic intervention are limited. The collaboration will create four new postdoctoral positions at the University of Oxford. 

Similar stories

NDORMS researchers awarded for Dupuytren research

Awards Hand Kennedy Main

Three NDORMS researchers have received awards from the International Dupuytren Society, a patient organisation that brings together Dupuytren Disease patient societies from across the world.

Hope for rheumatoid arthritis patients who are non-responsive to anti-TNF

Arthritis Kennedy Main

New research published in The Lancet shows that tocilizumab is a more effective treatment than rituximab for rheumatoid arthritis patients with a poor response to anti-tumour necrosis factor (TNF).

A new study maps the expression of innate immune receptors during the course of arthritis

Arthritis Kennedy Main

The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.

International Women's Day

Department Main

It’s International Women's Day! This year’s theme is #Choosetochallenge. We’re celebrating some of the amazing women at NDORMS, and asking them what changes they’d like to see in medical sciences over the next 100 years.

Patients and carers invited to join new group helping to shape research and treatment of bones, muscles and joints

Main PPI

Oxford’s newest patient partner group, OPEN ARMS launches today to explore the causes, treatment and care for patients with musculoskeletal conditions. Its first three patient partners explain why they are involved and invite other members of the public to join the team.

NDORMS academics named NIHR Senior Investigators

Main

Congratulations to Professor Jonathan Rees who has been announced as a National Institute of Health Research (NIHR Senior Investigator).